H ypertension poses a significant threat to public health. In industrialized countries, the life-time risk of developing hypertension exceeds 90%. 1 Hypertension greatly increases the risk of adverse cardiovascular outcomes such as ischemic heart disease (IHD) and heart failure (HF). 1 The disease is manageable, but the choice of treatment depends on an assessment of the total cardiovascular risk in the particular individual. Comorbidities play a significant role in this assessment, especially in individuals with only low to moderately increased blood pressure. 2 The role and cost efficiency of adding parameters derived from echocardiography to established risk factors in this assessment is unclear and possibly underinvestigated. 3 In the European Society of Hypertension/European Society of Cardiology 2013 guidelines for the management of arterial hypertension, echocardiography is only recommended under the suspicion of left ventricular (LV) hypertrophy, left atrial dilation or concomitant heart disease. 2 Echocardiographic parameters derived from 2-dimensional speckle tracking (2DSTE) strain imaging and tissue Doppler imaging have been demonstrated as powerful predictors of cardiovascular disease in the general population. 4, 5 Hence, these advanced echocardiographic methods may prove useful in the risk stratification of hypertensive individuals from the general population. Of particularly interest is global longitudinal strain (GLS), a parameter derived from 2DSTE demonstrated to contribute with independent prognostic value in HF with preserved ejection fraction, a condition in which established conventional indices of systolic function yield little prognostic value. 6 Because hypertension is closely associated with HF with preserved ejection fraction, GLS may offer unique value in risk stratification of hypertensive individuals. Both strain by 2DSTE and parameters by tissue Doppler imaging have been found to be impaired in hypertensive individuals, 7, 8 indicating potential prognostic value of both. However, the prognostic value of 2DSTE and tissue Doppler imaging in randomly selected hypertensive individuals from the general population without HF has not been well elucidated. Hence, this study seeks to determine the incremental prognostic value of echocardiography in both hypertensive and nonhypertensive individuals from the general population. Furthermore, this study aims to determine whether echocardiographic predictors of adverse cardiovascular outcome differ in hypertensive and nonhypertensive individuals from the general population, respectively.
Methods

Data Availability
This study uses data based on human patients. Therefore, the data are governed by the Danish Data Protection Agency. Any additional researcher who wishes to gain access to the data is required to file a formal application to the Danish Data Protection Agency. Therefore, the authors cannot grant access to the data used in this study unless anyone interested is approved by the Danish Data Protection Agency.
Study Sample
This study was based on data from participants in the Copenhagen City Heart study, a prospective cohort study designed to identify and asses risk factors for cardiovascular disease. The population is based in the city of Copenhagen, Denmark and has previously been described in detail. 4, 5 In this study, all participants who had an echocardiogram performed in the fourth round of examination spanning from 2001 to 2003 were initially included. Allocation of patients for echocardiograms during the fourth round of examination was independent of health status and risk factors. Exclusion criteria were prevalent HF, atrial fibrillation, significant valvular disease, and undetermined hypertension status. Furthermore, echocardiograms of insufficient quality for speckle tracking analysis were excluded. After exclusion criteria, 1294 participants remained for final inclusion into the study.
Ethics
Informed written consent was collected from all participants. The study design was approved by a regional ethics committee. Finally, the study complies with the Second Declaration of Helsinki.
General Health Examination
All participants underwent a general health examination. More detail is available in the online-only Data Supplement (Expanded Methods in the online-only Data Supplement). Briefly, blood pressure measurements were acquired using a sphygmomanometer and measured once. Hypertension was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg 2 or the use of antihypertensive medication. Nonfasted plasma glucose and hemoglobin A1c levels were measured in all participants. Participants were questioned for the use of glucose-lowering medications or a previous diagnosis of diabetes mellitus by a Danish physician. Diabetes mellitus was then defined as a nonfasted plasma glucose level >11.1 mmol/L or the use glucose-lowering medications or a previous diagnosis by a Danish physician or Hemoglobin A1c 7.0%. 9, 10 An abnormal ECG was defined as the presence of LV hypertrophy as defined by Minnesota code 3.1 or 3.3.
Echocardiography
All echocardiograms were performed using Vivid 5 ultrasound machines (GE Healthcare, Horten, Norway) with a 2.5 MHz transducer by 3 experienced sonographers. The protocol consisted of both conventional 2-dimensional echocardiography and color tissue Doppler imaging. Echocardiograms were stored on magneto-optical disks and on an external FireWire hard drive (LaCie, France). All echocardiograms were analyzed offline using commercially available software (EchoPac version 7.0.0; GE Healthcare, Horten, Norway).
Conventional and Color Tissue Doppler Echocardiography
Conventional and tissue Doppler echocardiography methodology is available in the online-only Data Supplement (Expanded Methods in the online-only Data Supplement).
Speckle Tracking Echocardiography
2DSTE was carried out in the 4-chamber, 2-chamber, and apical longaxis views. A total of 1294 echocardiograms were adequate for 2DSTE analysis. Mean frame rate was 57 frames/s (SD, 4 frames/s). GLS was calculated as the average of strain values from available views. A detailed description is available in the online-only Data Supplement (Expanded Methods in the online-only Data Supplement).
Follow-Up and Outcome
All participants were enrolled in 2001 to 2003 and followed until time to event or, in the case of no event, until October 2014. The end point was a composite outcome of either IHD or HF. All end points from the Copenhagen City Heart study were collected using International Classification of Diseases, Tenth revision (ICD-10) codes from the Danish National Board of Health's Patient Registry, and this has been described in more detail elsewhere. 4, 5 Follow-up was 100%.
Statistics
All statistical analysis was done using STATA 13.0 for Mac OS. Briefly, in Table 2 Cox regression was used to determine the prognostic value of examined parameters. Model 1 is adjusted for age, sex, smoking status, systolic blood pressure, diabetes mellitus, and total cholesterol levels. Model 2 is adjusted for the same variables as model 1 with the addition of GLS, LV mass index (LVMI), left atrial volume index, LV inner diameter at end diastole/height, heart rate, E/e′, a′, prevalent IHD, and abnormal ECG. In Table S1 (Table S1 in the online-only Data Supplement), net reclassification analysis 11 was used to determine the incremental prognostic value of GLS and LVMI when added to established risk factors. This was assessed in all, hypertensive, and nonhypertensive participants by adding LVMI and GLS (both as dichotomous variables stratified by the median) to a combined model consisting of SCORE and abnormal ECG status and to a combined model consisting of abnormal ECG status and a modified version American College of Cardiology/American Heart Association Pooled Cohort Equation 12 (race was excluded because our study consisted almost entirely of whites, whereas hypertension was excluded when considering only hypertensive or nonhypertensive participants). Because sex-specific cutoffs exist for LV hypertrophy determined by LVMI, 13 we also assessed the incremental prognostic value of stratifying the population according to LV hypertrophy. More detail is available in the online-only Data Supplement (Expanded Methods in the online-only Data Supplement).
Results
Population, Outcome, and Follow-Up
During a median follow-up of 12.5 years (interquartile range, 9.4-12.8 years), 222 participants (17.2%) developed the composite outcome consisting of HF or IHD. Out of these 222 events, 145 (65%) occurred in hypertensive participants, whereas 77 (35%) occurred in nonhypertensive individuals, corresponding to an incidence rate of 32 per 1000 personyears and 8 per 1000 person-years, respectively. Follow-up was a 100%.
Baseline Characteristics of the Population Stratified According to Hypertension Status
Hypertensive participants were significantly older and displayed a significantly higher prevalence of diabetes mellitus, IHD, and previous ischemic stroke (Table 1) . Furthermore, participants with hypertension displayed higher body mass index and heart rate ( Table 1) . Levels of total blood cholesterol were significantly higher in hypertensive participants, whereas estimated glomerular filtration rate values were significantly lower (Table 1) . Also, the prevalence of an abnormal ECG was significantly higher among participants with hypertension ( Table 1) .
Hypertensive participants exhibited significantly lower values of LV ejection fraction, GLS, E, E/A ratio, s′, and e′ 
Prediction of the Composite Outcome in Hypertensive and Nonhypertensive Participants
In univariable Cox regression, the following variables were revealed to be significant predictors of outcome in hypertensive participants: LV ejection fraction, GLS, LVMI, left atrial volume index, E/A, E/e′, deceleration time, and e′ (Table 2; Figure 1 ). Furthermore, the highest C statistic was displayed by LVMI and e′ ( Table 2 ). The same variables with the addition of E, A, s′, and a′ were found to be significant predictors of outcome in all participants and in nonhypertensive participants (Table 2; Figure 1 ). Generally, hazard ratios for all variables except a′ appeared to be lower in hypertensive participants compared with nonhypertensive participants (Table 2; Figure 1 ). Thus, with the exception of a′, identical changes in any 1 variable appeared to convey a lower increase in risk of reaching the composite outcome in hypertensive participants compared with nonhypertensive participants (Table 2; Figure 1 ). Furthermore, we found statistically significant interactions between A, E/A, E/e′, s′, e′, and a′, and the presence of hypertension (Table 2; Figure 1 ). Hence, identical changes in the variables A, E/A, E/e′, s′, e′ were found to convey a statistically significantly lower risk of reaching the composite outcome in hypertensive participants compared with nonhypertensive participants (Table 2; Figure 1 ). Finally, in hypertensive participants, decreasing values of a′ conveyed an increased risk of reaching the outcome, whereas in nonhypertensive participants, decreasing values of a′ conveyed a decreasing risk of reaching the composite outcome (Table 2; Figure 1 ).
Hypertensive participants were stratified by median LVMI and univariable Cox regression revealed hypertensive participants in the upper half of LVMI values to display an ≈2× greater risk of reaching the composite outcome compared with hypertensive participants in the lower half of LVMI values (Figure 2A) . Similarly, stratification of nonhypertensive participants according to median LVMI revealed participants in the upper half of LVMI values to display an ≈2× greater risk of reaching the composite outcome ( Figure 2B ). Hypertensive participants were stratified according to median GLS. Univariable Cox regression revealed hypertensive participants in the lower half of GLS values to display a 1.5× greater risk of reaching the composite outcome ( Figure 3A) . In nonhypertensive participants stratified according to median GLS, the risk associated with values in the lower half of GLS was ≈2.5× greater ( Figure 3B) .
In a multivariable model (model 1; Table 2 ) adjusting for age, sex, systolic blood pressure, smoking status, cholesterol levels, and diabetes mellitus, the following variables remained independent predictors of the composite outcome in hypertensive participants: LV ejection fraction, GLS, LVMI, left atrial volume index, E/e′, e′ and a′(model 1; Table 2 ). In nonhypertensive participants only LV ejection fraction, GLS, and LVMI remained independent predictors Model 1 is adjusted for age, sex, systolic blood pressure, smoking status, diabetes and total cholesterol. Model 2 is adjusted for the same variables as model 1 with the addition GLS, LVMI, LAVI, LVIDd/height, heart rate, E/e′, a′, prevalent IHD, and abnormal ECG. Only parameters reaching statistical significance in either hypertensive or nonhypertensive participants are shown. CI indicates confidence interval; DT, deceleration time; GLS, global longitudinal strain; HF, heart failure; HR, hazard ratio; IHD, ischemic heart disease; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; and RWT, relative wall thickness.
*In all participants, no stratification by hypertension was performed. Therefore, the multivariable models for all participants are additionally adjusted for hypertension. Table 2 ). When considering all participants, LV ejection fraction, GLS, LVMI, left atrial volume index, E/e′, and e′ remained independent predictors of outcome (model 1; Table 2 ). In a final multivariable (model 2; Table 2 ) adjusting for the same variables as model 1 with the addition of GLS, LVMI, left atrial volume index, LV inner diameter at end diastole/height, heart rate, E/e′, a′, prevalent IHD, and abnormal ECG, only LVMI remained an independent predictor of outcome in hypertensive participants (model 2; Table 2 ). In nonhypertensive participants, only GLS remained an independent predictor of outcome (model 2; Table 2 ). When considering all participants in the final multivariable model LVMI remained an independent predictor of outcome, whereas GLS was a borderline significant predictor of outcome (P=0.06; model 2; Table 2 ).
Incremental Prognostic Value of Echocardiographic Parameters in Hypertensive Participants
We assessed the incremental prognostic value of adding LVMI or GLS (both categorized into dichotomous variables by the median value) to a combined model consisting of SCORE risk factors and abnormal ECG status in all participants, in hypertensive participants and in nonhypertensive participants (Table S1 ). In hypertensive participants, LVMI significantly improved risk classification when added to the risk factors from SCORE and abnormal ECG status. However, this was not the case in nonhypertensive individuals. GLS improved risk classification when added to SCORE risk factors and abnormal ECG status in nonhypertensive but not in hypertensive individuals. However, both LVMI and GLS improved risk classification when considering all participants. We also assessed the incremental prognostic value of adding either LVMI or GLS to a modified version of the American College of Cardiology/American Heart Association Pooled Cohort Equation and abnormal ECG status in all participants, hypertensive participants, and nonhypertensive participants (Table  S1 ). Here, results were similar to the results from the SCORE risk chart analysis. Because sex-specific cutoffs exist for LV hypertrophy determined by LVMI, we assessed the incremental prognostic value of stratifying the population according to LV hypertrophy (Table S1 ). Here, results were similar to stratification by the median LVMI value.
Discussion
In this study, we demonstrate that LVMI offers incremental prognostic value over SCORE and abnormal ECG status in predicting a composite outcome of IHD and HF in hypertensive individuals from the general population. This prognostic value was also incremental to a modified version of the American College of Cardiology/American Heart Association Pooled Cohort Equation and abnormal ECG status. Furthermore, we show that in nonhypertensive individuals, GLS contributes with incremental prognostic information over established risk factors in predicting the composite outcome of IHD and HF. Hence, for the first time we demonstrate that hypertension status modifies the prognostic value of echocardiography in individuals from the general population.
Prognostic Value of LVMI Versus GLS in Hypertension
LVMI is a recognized independent risk factor for adverse outcome in essential hypertension, 2, 14 and this risk increases progressively with increasing LVMI, even in the low-to normal range. 15 This is in accordance with our results, because only LVMI remained an independent predictor of outcome in hypertensive participants in the final multivariable model, and because only LVMI significantly improved risk classification in addition to established risk factors in hypertensive participants.
As 2DSTE has increased in popularity and use, studies comparing hypertensive individuals to normal controls have described impaired myocardial strain values. 7, 8 In our study, we also found GLS by 2DSTE to be significantly lower in hypertensive individuals at baseline. GLS has recently been suggested as an optimal candidate for risk stratification of hypertensive individuals. 16 In hypertension participants from our study, GLS was only a significant predictor of outcome in univariable analysis and when adjusting for established risk factors. However, GLS did not add incremental prognostic value when added to established risk factors in hypertensive participants. Also, hazard ratios and C statistics for GLS appeared lower in hypertension participants compared with nonhypertensive participants, indicating small effect size to changes in GLS. Few studies have specifically evaluated the prognostic value of 2DSTE echocardiography in randomly selected hypertensive individuals from the general population. In a study of 120 hypertensive patients by Lee et al, 17 only epicardial longitudinal strain and neither GLS nor LVMI were significant predictors of a combined outcome of death, stroke, acute coronary syndrome, or HF. In their study, GLS and LVMI were not even significantly different between patients reaching the outcome and patients who did not reach the outcome. However, their study sample was Asian, Figure 2 . A, The curves depict the cumulative incidence of IHD and HF stratified by median LVMI in hypertensive individuals. B, The curves depict the cumulative incidence of IHD and HF stratified by median LVMI in nonhypertensive individuals. CI indicates confidence interval; HF, heart failure; HR, hazard ratio; IHD, ischemic heart disease; and LVMI, left ventricular mass index.
whereas ours was white. Because we did not determine epicardial longitudinal strain in this study, it is not possible to determine whether epicardial longitudinal strain would independently predict IHD and HF in our study sample, but part of the discrepancy in results may be because of ethnicity and limited sample size.
Our results support LVMI as a superior predictor of risk in hypertensive individuals from the general population. However, why GLS and other established echocardiographic parameters convey little prognostic information in hypertensive individuals is still not clear. It is known that hypertension greatly increases the risk of adverse cardiovascular outcomes in the general population. In accordance, the incidence rate of the combined outcome was 32 per 1000 person-years in hypertensive participants versus 8 per 1000 person-years in nonhypertensive participants in our study. Thus, we hypothesize that the greatly increased risk conveyed by hypertension dilutes the prognostic value of other echocardiographic parameters in the general population. Hazard ratios were lower for almost all echocardiographic parameters in both univariable and multivariable models in hypertensive participants compared with nonhypertensive participants. Thus, it is likely that many tested interactions would have been significant in case of a larger sample size, given the overall trend and borderline significance of particularly systolic parameters. Additionally, C statistics for almost all echocardiographic parameters also appeared to be lower in hypertension individuals in comparison to nonhypertensive individuals. Therefore, it seems that in hypertension individuals from the general population without fulminant cardiac disease LVMI is the most important echocardiographic parameter in predicting IHD and HF. The predictive value of LVMI may be because of its ability to quantify the extent of cardiac organ damage conveyed by hypertension on a continuous scale. This notion is supported by previous studies demonstrating that established markers of organ damage, including LVMI, are effective stratifiers of risk in hypertensive individuals from the general population. 2, 18 Thus, even when considering advanced echocardiographic measures such as GLS and TDI, only LVMI remained an independent predictor of outcome and added incremental prognostic information Figure 3 . A, The curves depict the cumulative incidence of IHD and HF stratified by median GLS in hypertensive individuals. B, The curves depict the cumulative incidence of IHD and HF stratified by median GLS in nonhypertensive individuals. GLS indicates global longitudinal strain; HF, heart failure; and IHD, ischemic heart disease.
in addition established risk factors in hypertensive individuals, in all likelihood because of its ability to gauge the severity of hypertension organ damage.
Different Predictors of Outcome in Hypertensive and Nonhypertensive Individuals
In participants free of hypertension, GLS and not LVMI contributed with incremental prognostic information in addition to established risk prediction models. These results are similar to other studies demonstrating independent prognostic value in predicting cardiovascular mortality and morbidity in the general population. 4 These results support our recently laid out hypothesis: in participants free of hypertension, subtle changes in GLS convey important information about relative risk of adverse cardiovascular outcome, and effectively stratifies individuals for risk of IHD and HF. However, in participants with hypertension and no fulminant cardiovascular disease, the subtle impairments observed in GLS and many other echocardiographic parameters do not constitute a significant relative risk compared with the risk conveyed by hypertension.
Limitations
Our study sample consisted mainly of whites, and therefore our results are not applicable to other races. Further studies replicating our findings in independent cohorts are needed. Whether public health may be improved by intervention guided by LVMI in hypertensive individuals would need to be assessed in a randomized fashion, randomizing individuals with high LVMI to intensified medication.
Conclusions
For the first time, we demonstrate that the prognostic value of echocardiography in predicting IHD and HF is altered by hypertension status in the general population. In hypertension individuals, LVMI added incremental prognostic value in addition to established prediction models and abnormal ECG status. In nonhypertensive individuals, GLS added incremental prognostic value in addition to established prediction models and abnormal ECG status.
Perspectives
Echocardiography has been suggested as an ideal method of improving risk stratification of hypertensive individuals from the general population. Current methods for prediction of cardiovascular disease in the general population relies on simple risk scores such as the SCORE. A more personalized approach to risk stratification may be beneficial. In the present study, we show that the echocardiographic predictors of adverse cardiovascular outcomes differ between hypertensive and nonhypertensive individuals. Thus, the presence of hypertension modifies the prognostic value of echocardiography in the general population. This suggests that adopting a more personalized approach to risk stratification of hypertensive and nonhypertensive individuals may be beneficial. More research into the differential prognostic value of echocardiography and other prognostic markers in hypertensive versus nonhypertensive individuals is needed to validate and extend on our findings.
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